论文部分内容阅读
目的综述了含哌嗪化合物作为受体配体的研究进展。方法综合国内外文献阐述了含哌嗪化合物作为多巴胺(DA)受体、5-羟色胺(5-HT)受体、α1肾上腺素受体(α1-AR)、黑皮质素-4受体(MC4R)以及σ受体配体等方面的最新研究概况。结果与结论含哌嗪化合物作为相应的受体配体具有广泛的生物活性,是目前研究开发的活跃领域之一,随着研究的不断深入,将有越来越多选择性高、药动学性质好的含哌嗪环药物应用于临床。
OBJECTIVE: The research progress of piperazine containing compounds as acceptor ligands is reviewed. Methods The synthesis of piperazine compounds as dopamine receptors, 5-hydroxytryptamine (5-HT) receptor, α1-adrenergic receptor (α1-AR), melanocortin-4 receptor (MC4R ) And sigma receptor ligands and other aspects of the latest research profile. RESULTS AND CONCLUSION Piperazine compounds, as the corresponding receptor ligands, have a wide range of biological activities and are currently one of the most active fields of research and development. As the research progresses, more and more high selectivity, pharmacokinetic Good properties with piperazine ring drugs used in clinical.